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Environmental health is the study of the environmen-
tal causes of disease in humans. There is general agree-
ment that most environmentally-induced diseases are 
characterized by a multifactorial etiology, and the cases 
attributable to a given exposure are indistinguishable 
in morphologic terms from those induced by different 
causal agents: the only observable difference is their 
diverse occurrence in subpopulation groups character-
ized by different exposure patterns. So, etiological-ep-
idemiological studies characterized by the adoption of 
sophisticated designs in terms of case definition, expo-
sure assessment, control of confounding and adequate 
statistical power, are required to estimate valid risk in-
dicators. Concurrently, another lesson learnt from envi-
ronmental epidemiology is that the general population 
includes susceptible or vulnerable subgroups, that can 
experience a higher burden of environmentally-induced 
disease than the general population, because of charac-
teristics like age and gender, genetic predisposition, or a 
higher sensitivity to well-defined, or undefined, chemi-
cal or physical agents. In this frame, Multiple Chemical 
Sensitivity (MCS) is described by clinical ecologists as 
a complex disorder with multisystemic symptoms that 
occur as a result of exposure to various environmental 
contaminants at concentrations below the threshold 
limit values (TLV) that, when and if fixed, are consid-
ered safe for the general population [1]. The main cat-
egories of chemicals involved in this process are: volatile 
organic chemicals (VOCs), apolar solvents [2], organo-
phosphate and carbamate pesticides with anticholines-
terase activity [3] and heavy metals. According to the 
toxicological theory, after chronic exposures or a single 
acute exposure, some more sensitive individuals may 
experience a progressive loss of tolerance – TILT the-
ory – [4, 5] with lowering of the threshold. This condi-
tion would cause an overreaction of the organism with 
particular implication of the central nervous system, 
limbic hyperactivity [2, 6] and other apparatuses and 
systems also following exposures to different classes of 
substances. It is under investigation if, due to particular 
metabolic polymorphisms in detoxification enzymes [7, 
8] and/or due to subsequent epigenetic modifications, 
these subjects would no longer be able to adequately 
detoxify their organisms, with an increase in free radi-
cals (hydroxyls and nitroso compounds) capable of 
causing inflammatory processes in different organs and 
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Abstract
On the international scene, Multiple Chemical Sensitivity (MCS) is defined, by several 
experts, as a multisystem syndrome that develops following chronic exposures to low 
doses of common chemical contaminants. Its general characteristics are, however, the 
object of conflicting opinions and a source of debate and research aimed at the appro-
priate nosological and therapeutic frameworks. In the face of a potentially debilitating 
trend, both in the occupational and in the economical and social sphere, the scientific 
community has not so far found an agreement. This problem leads patients and their as-
sociations to periodically claim some requests. The syndrome is also taken into consider-
ation at a political level, especially due to the close connection with the problems related 
to environmental pollution and to decision making in the field of control and prevention. 
For these reasons we believe that an appropriate widespread surveillance network for 
MCS should be set up in Italy, capable of intercepting possible cases, analyzing them at 
a multidisciplinary level, and following their evolution.
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tissues [2, 9]. The biomarker of inflammation, oxida-
tive stress, reduced or altered detoxification enzymes, 
are considered as possible early marker for MCS. The 
main route of exposure, especially in the workplace, ap-
pears to be inhalation. Anyway, the co-presence and co-
responsibility of dermal and oral absorption both in the 
initial awareness-raising phase and in the subsequent 
steps cannot be excluded. In some studies, an increase 
in the incidence of side effects from taking drugs [10] 
as well as some foods and beverages containing alcohol, 
caffeine and additives [4] has been found in these sensi-
tive people. The analysis of the genetic polymorphisms 
implicated in drugs metabolism, can highlight particu-
lar patterns that reduce the ability of detoxification 
and modify pharmacological efficacy. Hopefully, in the 
future, specific patterns of these polymorphism will be 
considered a risk factor to develop MCS and analyzed 
both for primary prevention and for appropriate dosage 
of therapies. 
Various chemical provocation studies have not so far 
provided unequivocal results [11] both in relation to 
the symptomatology tested, according to the substance 
administered by inhalation and in relation to the dose 
and time of administration. Some authors, hypothesiz-
ing the absence of a dose-response curve, have lowered 
the controlled administration even at doses lower than 
1% of the TLV or have used non-toxic substances but 
able to determine responses at the level of the olfactory 
organ and of the central nervous system.
A relatively recent review on this topic [11] reached 
the following conclusion: 
1.  the provocation and genotyping studies are still lim-
ited in number and the results are sometimes contro-
versial also due to the different diagnostic protocols 
adopted; 
2.  diagnostic certainty is difficult to meet because of 
multiplicity and non-specificity of symptoms. In the 
early stages, the results of the analyses carried on with 
current diagnostic techniques are generally negative; 
3.  although some diagnosis and treatment guidelines 
have been drawn up, there is still no agreement and 
standardization especially with regard to the defini-
tion of “case”, the relative inclusion/exclusion cri-
teria, the questionnaires and the clinical tests to be 
performed; 
4.  in the international scientific community, the debate 
is still ongoing with regards to the nosological clas-
sification;
5.  the Italian Ministry of Health has not yet recognized 
MCS as a disease and no specific disease code has so 
far been assigned to the syndrome in the latest ver-
sion of the International Classification of Diseases 
(ICD). 
With these premises, as further proof of the scientific 
interest and of the need to find answers, some Italian 
and foreign experts signed a consensus statement on 
MCS therapies and prevention strategies. This recent 
report, entitled “Resolution of Rome” [12] states that 
this syndrome requires a multidisciplinary approach 
and that health facilities must work together with social 
services to help patients obtain adequate rehabilitation 
and integration into an adequate environment both at 
workplace and at home. An updating of the literature 
in the last five years (2015-2019), focused on the Ital-
ian context, highlighted that some teams of experts are 
directing research on specific sectors of expertise, sub-
stantially in accordance with the international scientific 
literature.
One of the branches of research is the analysis of 
genetic variability in polymorphisms implicated in the 
detoxification of xenobiotics, in order to assess wheth-
er there are epidemiological findings that associate the 
presence of certain unfavorable variants in MCS to the 
onset of the syndrome. In some cases the differences 
in the levels of oxidative and nitrous stress were also 
evaluated in relation to a possible increase in the levels 
of cytokines in inflammatory processes [13, 14]. At the 
same time, the Tor Vergata University team is gradu-
ally confirming the hypothesis that limbic hyperreac-
tivity, combined with a hypoactivation of the cortical 
areas, is the mechanism underlying a hyper response 
to both odorous (hyperosmia/cacosmia) and acoustic 
stimuli, by using a sophisticated neuroimaging tech-
nique [15, 16]. Furthermore, the same authors also 
considered the audiological aspect of patients [17, 18]. 
Although audiometric tests have shown no functional 
abnormality in these patients, the suspected MCS have 
a greater sensitivity and intolerance to noise, correlated 
to an increase in anxiety, depression and stress. These 
results tend to confirm the hypothesis of limbic hyper-
reactivity without excluding the character traits due to 
hypervigilant personalities, as hypothesized in other 
studies. Two recent publications, which show positive 
results, must also be considered, although referring to 
MCS superimposed on other severe diseases. In these 
articles, positive responses were described in relation 
to the use of specific anaesthetics for thyroidectomy 
surgery [19] and to therapeutic treatment with citalo-
pram and/or Deep Transcranial Magnetic Stimulation 
[20]. The management of MCS patients poses particu-
lar problems in the establishment of the most appropri-
ate therapy and dosage, and this is a further focus of 
interest. 
In October 2018, the Italian National Institute of 
Health (ISS), hosted a multidisciplinary workshop on 
the available evidences and research needs (available on-
line as Supplementary Material). Altogether, these contri-
butions corroborated the notion of MCS as a syndrome 
that should be actively tracked, recognized, labeled and 
thereafter systematically investigated through a multi-
level longitudinal approach. Several Authors [21-25] 
have drawn up proposals for guidelines for the diagno-
sis and treatment of MCS that provide for an accurate 
medical record and implementation depending on the 
symptoms of multiple clinical and instrumental tests, 
thus also verifying the presence of other diseases. 
Accurate assessment of work environments present-
ing chemical risks can represent a good model of analy-
sis for the detection of MCS cases, including those who 
present other diseases already in treatment [22, 24]. 
Appropriate application of the law on safety and pro-
tection of workers should allow to intercept suspected 
cases when, from the initial phase of tolerance (suitabil-
ity for chemical risk), the first complaints about expo-
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sure-related illness arise. Environmental and biological 
real time monitoring should improve the assessment of 
the problem [11]. 
In this context, the possibility of highlighting a tol-
erance threshold valid also for the most sensitive sub-
jects is advisable. Risk characterization and assessment 
are very important in the whole process of defining 
the syndrome because the current gaps existing in the 
toxicological evaluation of substances and mixtures de-
termine difficulties in performing an adequate a priori 
risk assessment for these suspected sensitive individu-
als. According to us it is therefore appropriate to col-
lect epidemiological data through procedures capable 
of measuring exposure and to continue investigating 
genetic risk factors, markers of early exposure, acute 
and chronic effects. A deeper analysis is deserved by 
the modifications of physio biological parameters dur-
ing the acute episodes (systemic toxicology) that could 
highlight effects similar to those following toxic expo-
sure to certain categories of substances such as solvents 
and pesticides [11]. For example, the process of myo-
cardial sensitization to catecholamines, combined with 
a process of limbic hyperactivity, could explain some 
of the symptoms (tachycardia with or without arrhyth-
mia, tremors, dizziness, etc.) complained of by MCS 
patients, especially in the acute phases. The only partial 
reversibility of the process, as well as a possible undiag-
nosed damage through the currently available tests and 
instruments, could determine an exacerbation of the 
symptomatology following further exposures. Manage-
ment of the MCS patient is both symptomatic and by 
avoidance of the substances identified as possible acti-
vators. Psychological/psychiatric support therapy is also 
recommended. Due to the lamented disability resulting 
from this condition, it is important to know if a cer-
tain therapy is not only able to limit the symptom, but 
eventually allows the complete recovery of the ability to 
tolerate further re-exposure to the substances. 
It should also be emphasized that the absence of a 
scientific agreement on this syndrome leads patients to 
make periodic requests to the Government. This closes 
the cycle, switching the decision to a scientific level by 
requiring clarifications in the form of Parliamentary 
Questions that have been sent to the ISS over the years.
It’s necessary now to develop a national network of 
public centers able to diagnose potential cases of MCS, 
following a training initiative, designed by ISS together 
with the collaborating centers (Figure 1). This means 
building a national epidemiological surveillance sys-
tem for potential MCS cases by creating a network of 
centers that use a shared protocol. The availability of a 
national database of ascertained and suspected MCS 
patients, besides improving available scientific knowl-
edge on the patterns and natural records of the disease 
could also generate etiologic hypotheses, to be tested 
in the frame of ad hoc analytical epidemiologic studies. 
Parallel to the much-needed effort to define a consen-
sus on diagnostic procedures, equity in health care for 
these patients must be provided all over the country, 
avoiding the unbearable practice of health-driven mi-
gration. A new deal between MCS patients, politicians 
and the health system, on both national and regional 
level , appears to be necessary as it was also highlighted 
in a recent Italian Bill (Senate of the Italian Republic n. 
1272-XVIII Legislature). 
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Figure 1
This is a possible information flow chart that provides for the sharing of medical records of suspected cases of mcs between the 
centers and the Italian National Institute of Health (ISS), in absolute respect of privacy. The aim is both performing general asses-
sments for the verification of a single diagnostic protocol and both subsequently allow to set up a Register of Italian MCS cases, 
coordinated by the Institution.
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